Manila, Philippines - The Department of Health (DOH) has officially stated its stance against the use of injectable glutathione for skin whitening purposes.
According to Philippines News Agency, the DOH emphasized that the Food and Drug Administration (FDA) Philippines only approves injectable glutathione as an adjunct treatment in cisplatin chemotherapy, a treatment for advanced cancers of the bladder, ovaries, or testicles, and not for skin lightening.
The DOH's statement highlighted FDA Circular No. 2019-182, which clearly indicates the absence of clinical trials evaluating injectable glutathione for skin lightening purposes. Furthermore, there are no established guidelines for safe dosing regimens or treatment durations for such use. The department reminded the public that while the FDA approves prescription drugs for market entry in the Philippines, it does not regulate how doctors prescribe these drugs to their patients.
Additionally, the FDA pointed out the health risks associated with the use of injectable glutathione for skin whitening, including potential harm to the liver, kidneys, and nervous system. There is also a risk of developing Stevens Johnson Syndrome, a severe condition affecting the skin and mucous membranes. The agency also raised concerns about the long-term risk of skin cancer due to changes in melanin production caused by glutathione.
The combination of injectable glutathione with intravenous Vitamin C, a common practice, may increase the risk of kidney stones, especially in individuals with acidic urine. The FDA also warned against the potential transmission of infectious agents like HIV, hepatitis C, and B, particularly when treatments are administered by non-medical practitioners or in non-sterile facilities.
For those who believe they have been wrongly prescribed injectable glutathione, the DOH advises consulting with a lawyer or the Public Attorney's Office for guidance on medical negligence. Individuals experiencing side effects from any drug, including injectable glutathione, should seek immediate medical attention and report their case to the FDA.